title: Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
abstract: All patients with acute lymphoblastic leukemia (ALL) over age 60 years seen at Princess Margaret Hospital over an 11-year period were analysed retrospectively. Of 53 patients, 45 received multiagent induction chemotherapy using a variety of regimens. There were 13 BCR-ABL positive patients, 9 of who received imatinib mesylate, either during induction or post-remission therapy. The overall complete remission (CR) rate of all 45-induction patients was 56%, with a 27% induction-related mortality rate. The CR rate was not influenced by induction regimen, age, initial WBC, LDH or BCR-ABL status. The median overall survival of the induction patients was 9 months, while the median progression-free survival (PFS) of the patients achieving CR was 10 months. The estimated overall survival (OS) at 3 years was 18.4% (95% CI: 9.8-34.3%). Age and initial WBC did not significantly predict for OS when evaluating the entire group of induction patients. However, there was a strong trend for BCR-ABL status to favorably predict for PFS, and for OS when only patients treated after July 2000 (when imatinib became available) were evaluated. The results indicate that ALL remains a poor prognosis disease in elderly patients, and that aggressive induction regimens designed for younger patients are very toxic for these patients. These data suggest that BCR-ABL+ ALL is becoming a relatively more favorable prognosis disease in the elderly, likely due to the influence of imatinib therapy. Further regimens should explore the use of less aggressive regimens in elderly patients and should evaluate the optimal way of combining imatinib with conventional agents in BCR-ABL+ patients.
authors.affiliation: Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ont., Canada. joseph.brandwein@uhn.on.ca
authors.forename: J M
authors.initials: JM
authors.lastname: Brandwein
authors.forename: V
authors.initials: V
authors.lastname: Gupta
authors.forename: R A
authors.initials: RA
authors.lastname: Wells
authors.forename: A C
authors.initials: AC
authors.lastname: Schuh
authors.forename: A D
authors.initials: AD
authors.lastname: Schimmer
authors.forename: J H
authors.initials: JH
authors.lastname: Lipton
authors.forename: H A
authors.initials: HA
authors.lastname: Messner
authors.forename: Q-L
authors.initials: QL
authors.lastname: Yi
authors.forename: K
authors.initials: K
authors.lastname: Chun
authors.forename: S
authors.initials: S
authors.lastname: Kamel-Reid
authors.forename: M D
authors.initials: MD
authors.lastname: Minden
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D005260:Female; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl